{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8"},{"groupId":"OG002","value":"23.2"},{"groupId":"OG003","value":"11.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"509"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"125"},{"groupId":"OG003","value":"124"}],"units":"Participants"}],"title":"Drug Discontinuation with Enzalutamide or Placebo"},{"categories":[{"measurements":[{"groupId":"OG001","value":"7.7"},{"groupId":"OG002","value":"23.2"},{"groupId":"OG003","value":"12.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"125"},{"groupId":"OG003","value":"124"}],"units":"Participants"}],"title":"Drug Discontinuation with Abiraterone"},{"categories":[{"measurements":[{"groupId":"OG001","value":"7.7"},{"groupId":"OG002","value":"16.0"},{"groupId":"OG003","value":"12.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"125"},{"groupId":"OG003","value":"124"}],"units":"Participants"}],"title":"Drug Discontinuation with Prednisone"}],"denoms":[{"counts":[{"groupId":"OG000","value":"509"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"125"},{"groupId":"OG003","value":"124"}],"units":"Participants"}],"description":"An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Outcome of an AE was response to a question answered by the investigator: 'Is the AE leading to study discontinuation or death?' as 'yes'.","groups":[{"description":"Participants who only received enzalutamide 160 mg as four 40 mg capsules, orally once daily in the study.","id":"OG000","title":"Enzalutamide 160 mg"},{"description":"Participants who received (after switching from enzalutamide), abiraterone 1000 mg as four 250 mg tablets, orally once daily and prednisone 10 mg administered as two 5 mg tablets, orally twice daily in the study.","id":"OG001","title":"Enzalutamide Crossing Over to Abiraterone + Prednisone"},{"description":"Participants who received enzalutamide 160 mg as four 40 mg capsules, orally once daily along with abiraterone 1000 mg as four 250-mg tablets, orally once daily and prednisone 5 mg tablet, orally twice daily in the study.","id":"OG002","title":"Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg"},{"description":"Participants who received placebo matched to enzalutamide as four 40 mg capsules, orally once daily along with abiraterone 1000 mg as four 250-mg tablets, orally once daily and prednisone 5 mg tablet, orally twice daily in the study.","id":"OG003","title":"Placebo+Abiraterone 1000mg+ Prednisone 10mg"}],"paramType":"NUMBER","populationDescription":"Safety population included all participants who received any amount of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (maximum of 99.4 months)","title":"Percentage of Participants With Adverse Events (AEs) Leading to Study Drug Discontinuation","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of participants"}